Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 53Neoplasm Metastasis 5Uterine Neoplasms 2Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Ovarian Neoplasms 2Colorectal Neoplasms 2Urologic Neoplasms 1Urogenital Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Neoplasms by Site 1Neoplasms 1Malignant Neoplasms of Female Genital Organs 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Liposarcoma 1Hormone Receptor Positive Breast Carcinoma 1Head and Neck Neoplasms 1HR-positive, HER2-negative Breast Neoplasms 1HER2-positive Metastatic Breast Cancer 1Genital Neoplasms, Female 1Genetic Diseases, Inborn 1Estrogen Receptor Positive Breast Cancer 1Endometrial Neoplasms 1ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Lobular 1

Interventions

Dexamethasone 18Cyclophosphamide 16fludarabine 11pomalidomide 9pembrolizumab 9carfilzomib 9daratumumab 7Rituximab 7Lenalidomide 7Calcium Dobesilate 7fludarabine phosphate 6Cisplatin 6Bortezomib 6Gemcitabine 5venetoclax 4elotuzumab 4isatuximab 3Vincristine 3Radiotherapy 3Prednisone 3Letrozole 3Etoposide 3Doxorubicin 3Cytarabine 3tisagenlecleucel 2selinexor 2ruxolitinib 2palbociclib 2ixazomib 2dexamethasone 21-phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Recurrence × Fulvestrant × Clear all
NCT05154487 2026-03-03

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

GOG Foundation

Phase 2 Active not recruiting
51 enrolled

Recurrence

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Pfizer

Phase 2 Active not recruiting
333 enrolled
Breast

Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡